The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
|Articles|November 1, 2003
Established patients: How to determine the proper level
Author(s)Ray Painter, MD
Instructions for coding for all Evaluation and Management (E&M) services have several elements in common. One should always base documentation and coding on the amount of work required to provide good patient care.
Advertisement
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Advertisement
Advertisement
Trending on Urology Times
1
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
2
Jeffrey M. Spier, MD, on the evidence for reduced-dose enzalutamide
3
Prostate Cancer Case Review: Selecting Radioligand Therapy Candidates
4
Prostate Cancer Case Review: PSMA PET Before Definitive Therapy
5